# Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials

> **Open Intelligence Dossier** · First detected: 2026-11-08 23:20 UTC · Category: Business

## Executive Summary
Eli Lilly's experimental triple-hormone drug retatrutide cut knee osteoarthritis pain and produced average weight loss of roughly 25% in two Phase 3 trials involving more than 1,000 adults with obesity.

## Intelligence Brief
Eli Lilly&#039;s investigational obesity drug retatrutide significantly reduced knee osteoarthritis pain and improved physical function in two Phase 3 trials, TRIUMPH-1 and TRIUMPH-4, according to data presented at the American College of Rheumatology Convergence 2026 meeting and published simultaneously in the New England Journal of Medicine. In TRIUMPH-4, led by Thomas Conaghan, MBBS, PhD, of the University of Leeds, 445 patients with obesity (BMI &gt;27) and knee OA from the U.S., Canada, Mexico, Australia, and Spain were randomized to placebo or 9 mg or 12 mg weekly subcutaneous retatrutide. Baseline characteristics included mean BMI of 40.4, mean weight of 113 kg (249 lbs), 63% women, two-thirds white, and 64% with Kellgren-Lawrence grade 3 joint damage. All participants received individualized dietary counseling and a physical activity program targeting at least 150 minutes per week.


At week 68, WOMAC pain scores fell by 4.48 points with 9 mg and 4.41 points with 12 mg versus a 2.43-point decline with placebo (baseline average 5.95). Physical function scores improved by 4.14 and 4.20 points respectively versus 2.06 points with placebo. In a responder analysis, about 70% of patients in both retatrutide arms achieved a 70% reduction in WOMAC pain versus 26% on placebo. Average weight loss exceeded one-quarter of body weight at 68 weeks, with losses approaching 7% by week 8 and continuing without an obvious plateau; some patients withdrew because they considered the weight loss excessive. High-sensitivity C-reactive protein fell by half with retatrutide versus a 25% reduction with placebo, and triglycerides and non-HDL cholesterol also improved significantly.


Adverse events led to discontinuation in 13% of the 9 mg group and 18% of the 12 mg group versus 4% on placebo. Serious adverse events occurred in about 10% of retatrutide recipients versus 2% on placebo. Gastrointestinal events were most common; fatigue, dizziness, headache, urinary tract infections, and increased skin sensitivity (12% at the higher dose, none on placebo) occurred at two to four times the placebo rate. Conaghan noted adverse events appeared more common in patients with BMI


A second Northwestern University-led trial, described by corresponding author Dr. Thomas Schnitzer of Feinberg School of Medicine, similarly showed average weight loss up to 25% and around two-thirds of active-treatment recipients reporting at least a 50% reduction in knee OA pain, while placebo recipients self-reported a 38% reduction. Schnitzer said, &quot;The findings are really saying for people who are overweight and have OA, if you lose a significant amount of weight with this treatment, there is a good chance that you&#039;re going to get a meaningful reduction in your knee pain.&quot; He added that many participants lost considerable weight, &quot;with a few losing up to a hundred pounds or more.&quot; Both Schnitzer and the NEJM authors emphasized that mechanisms beyond mechanical unloading — such as potential anti-inflammatory effects of GLP-1 receptor agonists — remain unclear and require further study, including whether metabolically normal OA patients could benefit without unhealthy weight loss. Retatrutide is a triple agonist of GLP-1, glucagon, and GIP receptors, a mechanism distinct from single- or dual-agonist drugs such as semaglutide and tirzepatide. It currently has FDA approval only for compassionate use, reportedly granted to just one American. Eli Lilly highlighted the data alongside updates for Zepbound (tirzepatide) and Taltz (ixekizumab) at the ACR meeting.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Medical Professionals Reference | Weekly Retatrutide Reduces Knee Osteoarthritis Pain and Weight | [Source Link](https://news.google.com/rss/articles/CBMiigFBVV95cUxOZGxDdmZzU3FodC1CVDhqME9wNVdRX0NfWXdITi1UZFZ2X19Ga08yOWNuUmR1MVlTQXVtams5ZzdxOHJOdjAzbkhVY3hycEJ3ODBUNVdKLTFGVGpyZnNmMDNmVnJfa2xPenQ2UDAxTnBmSjZwcGlDYnNJbXpqNnlIRzZWVFN2OWZzaUE?oc=5) |
| Medscape | Retatrutide Improves Knee OA Pain, Physical Function | [Source Link](https://news.google.com/rss/articles/CBMiqAFBVV95cUxPd3p1emJDT0JCUkc1VHNmc2duNnN5bFJmTnpZS0pIYVRVREl5aHA5MlNUUm11UE9lUHR0MDZYaU5OdEVUUGI5M1VWRERoYTktNkFOd3Y1ZGN3OXJjMF9INEJmTGd4a2Z1dWlnMnFzOVRpdXlIbVhMZjBiajM3RThTWjJQQUU1M3VPUTJ1WmRpRXNnVHZZMXZfRXRZelpBdFdQU0ljbUowWmo?oc=5) |
| Crain's Chicago Business | Northwestern researchers find Lilly’s new weight-loss drug may improve bad knees | [Source Link](https://news.google.com/rss/articles/CBMipAFBVV95cUxPalZlalY5RzlXSTEyaGphb3ZPcFc2UlctT0lVTW50ekhUVDRWMWVodTc5b2VLTUEwZlpJUkZjLTROYkF2S1U5ODlUNXY1V2ZCWlhaREFCR1F0SkZzTU9qYmZXaVB4MGNLUk5kYXRIdE1XeTRxR2JDYTJQdllrTjhpd21fUHVSbXZ5UkJaZDlWczQwT1dNdVNmVklBTkVvVG5zN1BYVg?oc=5) |
| 조선일보 | Eli Lilly's Retatrutide Reduces Weight, Knee Pain | [Source Link](https://news.google.com/rss/articles/CBMiiAFBVV95cUxNbXhZR1h4TnhBdTlFMzZoZ3FtY29mOHk5azNnTWlaWHlVYW9Cdm54TksxeEhybnZDbFNxaVMtSy1WZUNDTmxYc0NGS0tSSWlIeWhrR1VOS3RuLXNJbGV0VEYxYXY2ODk2aTdaTlVzR29PMjk2QjZ4M3FTbFAzWnF6SHQtdWlkS3Y2?oc=5) |
| Eli Lilly | Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity | [Source Link](https://news.google.com/rss/articles/CBMivwFBVV95cUxONW0zckVoYndtZlBsLVB0MEVlRkQtUlFaYWMzbEVQT0VfR3lkUm1lU0NqcHFaek40REVhQ0lkeUFBNlJ2MlVReTZudkY3dmU2NjJucWRQcmJsNk96YzJFMWRXcXRJUUxGRnY3YURBM3Jld0tQRjE0MVpHUzNoX3QxTkh0Y2NnMzRWNjlLUHNXb2QyZE0zYmRySHM3RkwtblZQNjhZMjcwcmxKYTRTZV9NWEZzQWJqaEZZd3RMUXZSYw?oc=5) |
| Yahoo Finance | Eli Lilly (LLY) Highlights ACR Data, Is The Stock Still 8% Undervalued? | [Source Link](https://news.google.com/rss/articles/CBMimAFBVV95cUxQMGtNOExVb3JPSk1UM05TVWRual9rNVgtWHF3TTVqN24yNDFCUjY1ZngwN3YyX2h0V3JyQWpfZjZDYzh5MTVDNnBYdWJBc0xfZjRLTnZub2x5bmNfNEJsT3VjSkIzNkRWR3I0cEd4VFB2WG1GM3RZWUktdlU0WnpVMFJ6bjd4bTRYbE1BZmY2a3VZdUtoWkp2YQ?oc=5) |
| MedPage Today | Triple-Target Incretin Drug Kills Knee Osteoarthritis Pain in Obesity | [Source Link](https://news.google.com/rss/articles/CBMiZkFVX3lxTE5Kd0VlN25YU0hYeE5FWnZzN1NndWN3OUY2cnZ2VHJDazZtZ1RIeDN5SlpQcnZLSHlaY3lHaUIwczZKcXlWZzZ6VTNUN0hmNXFqU0ZHdTZBaXBUdk1NUkpwempUS3h1UQ?oc=5) |
| New Atlas | Knee osteoarthritis pain relief – and massive weight loss – from new GLP-1 | [Source Link](https://news.google.com/rss/articles/CBMiiAFBVV95cUxOdGhUblRSNWxURUZ3NUNsRmxpOUJxWE9zLTVfVF8yU3FWdUNpYXV2OVFGVmp5aVk0ZlFBOTlPeTZhUFVKVUpsWnU2QUZmaE0tNXBxZWJVSFBrYmEwMUlnME01aFFCaUd3WXFLWlVpSGpmaGxwMnFHenczVVoyZW9UTWppZUlFNkhQ?oc=5) |
| Medical Xpress | Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials | [Source Link](https://news.google.com/rss/articles/CBMihgFBVV95cUxQaTNVb2RoOFV0NFZGNWR4d3E5QS05N0VFVVZKLW5iUGVTYlBMY2NSdy1UTlM4d3ZUUUNkNjdsNVdBWUdtM1o3aWxLbUJ0NVRxaVZtbnNfUUVYczVGdU1NTFZjcWZmbGVLV3NjTGRWWjVwc21wdU5zNm1GUGtEbVBxcWJPcHlVdw?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-11-08/experimental-weight-loss-drug-eases-painful-knee-osteoarthritis-in-two-clinical*
